Predictive and Prognostic Value of Excision Repair Cross-complementing Group 1 in Patients with Advanced Gastric Cancer

Overview

Journal BJC Rep

Publisher Nature Portfolio

Date 2024 Nov 8

PMID 39516666

Authors

Yasuhide Yamada

Kengo Nagashima

Mizutomo Azuma

Mitsuko Masutani

Hitoshi Ichikawa

Satoru Iwasa

Naoki Takahashi

Hidekazu Hirano

Keisuke Kanato

Nozomu Machida

Takahiro Kinoshita

Hiroaki Hata

Hisato Kawakami

Daisuke Takahari

Narikazu Boku

Yukinori Kurokawa

Masanori Terashima

Takaki Yoshikawa

Shigeki Sekine

Nobuyoshi Hiraoka

Affiliations

Soon will be listed here.

Abstract

Background: To define the optimal chemotherapy regimen for each patient we therefore used tissue from patients to identify molecular prognostic or predictive biomarkers.

Methods: Endoscopic biopsy specimens from primary lesions and surgical specimens on a phase III trial in patients with unresectable advanced or recurrent gastric cancer treated with docetaxel with cisplatin plus S-1 (DCS) or cisplatin plus S-1 (CS), were collected. We measured the mRNA expression of ERCC1 and analyzed SNPs in GSTP1 and ERCC1.

Results: Low ERCC1 expression was associated with favorable prognosis for overall survival, OS by multivariable analysis (P = 0.001). There were significant interactions between the two treatment arms of DCS and CS, and ERCC1 mRNA expression. In patients with low ERCC1 expression of a favorable prognosis, DCS therapy was inferior to CS (P = 0.046). In addition to GSTP1 rs1695 (HR 1.728), ERCC1 rs3212980, ERCC1 rs2298881, ERCC1 rs3212964 with high expression of ERCC1 mRNA were associated with significantly worse prognosis with regard to OS.

Conclusions: ERCC1 mRNA is an independent prognostic factor and predictive marker that can be used to guide the addition of docetaxel. The SNPs of ERCC1 and GSTP1 could be also prognostic or predictive factors.

References

Liu J, Liu Q, Li L . Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcomes of patients with advanced non-small cell lung cancer. Genet Mol Res. 2015; 14(3):10331-7. DOI: 10.4238/2015.August.28.19. View

. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14(2):101-12. DOI: 10.1007/s10120-011-0041-5. View

Kang Y, Yook J, Park Y, Lee J, Kim Y, Kim J . PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021; 39(26):2903-2913. PMC: 8425847. DOI: 10.1200/JCO.20.02914. View

Horikoshi T, Danenberg K, Stadlbauer T, Volkenandt M, Shea L, Aigner K . Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res. 1992; 52(1):108-16. View

Grenader T, Waddell T, Peckitt C, Oates J, Starling N, Cunningham D . Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial. Ann Oncol. 2016; 27(4):687-92. DOI: 10.1093/annonc/mdw012. View

Hertz D, Kidwell K, Thibert J, Gersch C, Regan M, Skaar T . Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. Mol Oncol. 2015; 9(9):1868-76. PMC: 4624024. DOI: 10.1016/j.molonc.2015.07.002. View

Wang J, Zhou X, Li J, Cheng J, Zeng X, Li X . Prognostic significance of ERCC1 expression in postoperative patients with gastric cancer. Chin J Cancer Res. 2014; 26(3):323-30. PMC: 4076725. DOI: 10.3978/j.issn.1000-9604.2014.06.07. View

Friboulet L, Olaussen K, Pignon J, Shepherd F, Tsao M, Graziano S . ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013; 368(12):1101-10. PMC: 4054818. DOI: 10.1056/NEJMoa1214271. View

Zou M, Hu X, Xu B, Tong T, Jing Y, Xi L . Glutathione S‑transferase isozyme alpha 1 is predominantly involved in the cisplatin resistance of common types of solid cancer. Oncol Rep. 2018; 41(2):989-998. DOI: 10.3892/or.2018.6861. View

10.

Lv Y, Xu M, Sun Y, Liu Y, Zhao L, Liu X . Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2021; 100(33):e26850. PMC: 8376342. DOI: 10.1097/MD.0000000000026850. View

11.

Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T . Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer. 2008; 98(4):832-9. PMC: 2259181. DOI: 10.1038/sj.bjc.6604211. View

12.

Metzger R, Leichman C, Danenberg K, Danenberg P, Lenz H, Hayashi K . ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 1998; 16(1):309-16. DOI: 10.1200/JCO.1998.16.1.309. View

13.

Van Cutsem E, Moiseyenko V, Tjulandin S, Majlis A, Constenla M, Boni C . Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24(31):4991-7. DOI: 10.1200/JCO.2006.06.8429. View

14.

Al-Batran S, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S . Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma.... Lancet. 2019; 393(10184):1948-1957. DOI: 10.1016/S0140-6736(18)32557-1. View

15.

Thompson L, Brookman K, Jones N, Allen S, Carrano A . Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatid exchange. Mol Cell Biol. 1990; 10(12):6160-71. PMC: 362891. DOI: 10.1128/mcb.10.12.6160-6171.1990. View

16.

Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A . Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci. 2019; 110(4):1480-1490. PMC: 6447843. DOI: 10.1111/cas.13969. View

17.

Cobo M, Isla D, Massuti B, Montes A, Miguel Sanchez J, Provencio M . Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007; 25(19):2747-54. DOI: 10.1200/JCO.2006.09.7915. View

18.

Kim J, Kim M, Kim T, Lee S, Kim D, Im S . Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer. 2009; 100(5):732-8. PMC: 2653762. DOI: 10.1038/sj.bjc.6604936. View

19.

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97(16):1180-4. DOI: 10.1093/jnci/dji237. View

20.

Yamada Y, Boku N, Nishina T, Yamaguchi K, Denda T, Tsuji A . Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912. Ann Oncol. 2013; 24(10):2560-2565. DOI: 10.1093/annonc/mdt238. View